Organovo Completes Sale of FXR Program to Eli Lilly
Deal News | Mar 25, 2025 | Globenewswire
Organovo Holdings, Inc., a clinical-stage biotechnology company specializing in novel treatment approaches for inflammatory bowel disease, has successfully completed the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company. The transaction closed on March 25, 2025, and involves an upfront payment to Organovo, with additional payments contingent upon the achievement of future regulatory and commercial milestones. Eli Lilly has acquired all commercial and intellectual property rights to Organovo's FXR program and will assume responsibility for all future clinical development. Organovo is known for developing drugs using 3D human tissues that simulate native tissue properties, while Lilly's acquisition aligns with its ongoing efforts to enhance its therapeutic pipeline. The financial specifics of the transaction remain undisclosed.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United States – Both Organovo and Eli Lilly are based in the United States, highlighting the domestic nature of this transaction.
Industry
- Biotechnology – Organovo operates in the biotechnology sector, focusing on drug development using 3D human tissues, exemplifying innovation in biomedical technology.
- Pharmaceuticals – Eli Lilly, a major pharmaceutical company, is enhancing its drug development pipeline through acquisitions like Organovo's FXR program.
Financials
- Not Disclosed – The financial terms of the transaction, including the upfront payment and potential future milestone payments, were not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Organovo Holdings, Inc. | Target Company | Company | A clinical-stage biotechnology company specializing in drug development using 3D human tissues. |
| Eli Lilly and Company | Bidding Company | Company | A leading pharmaceutical company acquiring Organovo's FXR program for global development. |